PTX 2.44% 4.0¢ prescient therapeutics limited

Ann: Prescient to Present at AVID 2022 Meeting, page-13

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 40 Posts.
    lightbulb Created with Sketch. 256
    Hi Shellbell,

    I think the data is good, but from my understanding the only new info contained related to specifics on how the version 003 is optimised (which is the version they used in the switching study) vs previous versions (which Penn used in the proof of concept). Little bit on amount of binder required, which is nice from regulatory / cogs too. The way I see it, the data is interesting and backs up SYC's and Rebecca's previous comments about v3, but it is not particularly game changing in itself.

    The re-arming and re-targeting data is the important stuff but has been previously announced and followed with several presentations from SYC.

    Hopefully more new data to come soon from new studies.. including the cell therapy enhancements which will probably be next.

    Cheers
    CB

 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.0¢
Change
-0.001(2.44%)
Mkt cap ! $32.21M
Open High Low Value Volume
4.2¢ 4.2¢ 4.0¢ $43.30K 1.062M

Buyers (Bids)

No. Vol. Price($)
12 1110555 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 60000 1
View Market Depth
Last trade - 14.47pm 04/11/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.